DK1490490T3 - Antisense IAP--nukleobase-oligomerer og anvendelser deraf - Google Patents
Antisense IAP--nukleobase-oligomerer og anvendelser derafInfo
- Publication number
- DK1490490T3 DK1490490T3 DK03715244T DK03715244T DK1490490T3 DK 1490490 T3 DK1490490 T3 DK 1490490T3 DK 03715244 T DK03715244 T DK 03715244T DK 03715244 T DK03715244 T DK 03715244T DK 1490490 T3 DK1490490 T3 DK 1490490T3
- Authority
- DK
- Denmark
- Prior art keywords
- nucleobase oligomers
- antisense iap
- iap
- antisense
- oligomers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36785302P | 2002-03-27 | 2002-03-27 | |
PCT/IB2003/001670 WO2003080638A2 (en) | 2002-03-27 | 2003-03-27 | Antisense iap nucleobase oligomers and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1490490T3 true DK1490490T3 (da) | 2009-09-07 |
Family
ID=28454856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK03715244T DK1490490T3 (da) | 2002-03-27 | 2003-03-27 | Antisense IAP--nukleobase-oligomerer og anvendelser deraf |
Country Status (17)
Country | Link |
---|---|
US (5) | US7091333B2 (da) |
EP (1) | EP1490490B1 (da) |
JP (2) | JP4486365B2 (da) |
CN (1) | CN1656222B (da) |
AT (1) | ATE431410T1 (da) |
AU (1) | AU2003219432B2 (da) |
BR (1) | BR0308923A (da) |
CA (1) | CA2480308C (da) |
DE (1) | DE60327618D1 (da) |
DK (1) | DK1490490T3 (da) |
ES (1) | ES2325660T3 (da) |
IL (2) | IL164228A0 (da) |
MX (1) | MXPA04009361A (da) |
NZ (3) | NZ546807A (da) |
PT (1) | PT1490490E (da) |
WO (1) | WO2003080638A2 (da) |
ZA (1) | ZA200407649B (da) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6156535A (en) * | 1995-08-04 | 2000-12-05 | University Of Ottawa | Mammalian IAP gene family, primers, probes, and detection methods |
US6133437A (en) * | 1997-02-13 | 2000-10-17 | Apoptogen, Inc. | Modulation of IAPs for the treatment of proliferative diseases |
US20070026394A1 (en) | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
WO2005078097A2 (en) | 2004-02-10 | 2005-08-25 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (Multifunctional siNA) |
GB2406568B (en) * | 2002-02-20 | 2005-09-28 | Sirna Therapeutics Inc | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
NZ546807A (en) | 2002-03-27 | 2007-03-30 | Aegera Therapeutics Inc | Antisense IAP nucleobase oligomers and uses thereof |
EP1927665A3 (en) * | 2002-11-19 | 2008-10-29 | CLLUone Therapeutics A/S | Methods and kits for diagnosing and treating b-Cell chronic lymphocytic leukemia (B-CLL) |
BRPI0410886A (pt) * | 2003-06-03 | 2006-07-04 | Isis Pharmaceuticals Inc | composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único |
US8575327B2 (en) | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
US20050148535A1 (en) * | 2003-10-30 | 2005-07-07 | Lacasse Eric | IAP nucleobase oligomers and oligomeric complexes and uses thereof |
US8012944B2 (en) | 2003-10-30 | 2011-09-06 | Pharmascience Inc. | Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent |
CA2552937A1 (en) * | 2004-02-05 | 2005-08-18 | Novartis Ag | Combination of (a) a dna topoisomerase inhibitor and (b) an iap inhibitor |
EP1586654A1 (en) * | 2004-04-15 | 2005-10-19 | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg | Replication competent viruses capable of silencing virus inhibitory factor expression |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
JP2008513507A (ja) * | 2004-09-17 | 2008-05-01 | アイシス ファーマシューティカルズ インコーポレイティッド | 増強されたアンチセンスオリゴヌクレオチド |
US20080293653A1 (en) * | 2004-10-14 | 2008-11-27 | Jon Durkin | Method of treating autoimmune diseases |
TWI401316B (zh) * | 2004-12-23 | 2013-07-11 | Alcon Inc | 用於治療青光眼之血清澱粉樣蛋白A的RNAi抑制作用 |
WO2007035759A1 (en) * | 2005-09-19 | 2007-03-29 | Johnson & Johnson Pharmaceutical Research & Development L.L.C. | Modulation of glucocorticoid receptor expression |
JP4557051B2 (ja) * | 2008-06-17 | 2010-10-06 | セイコーエプソン株式会社 | プロジェクタ |
JP6106085B2 (ja) | 2010-08-24 | 2017-03-29 | サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. | 内部非核酸スペーサーを含む一本鎖RNAi剤 |
DK2632472T3 (da) | 2010-10-29 | 2018-03-19 | Sirna Therapeutics Inc | Rna-interferensmedieret hæmning af genekspression ved anvendelse af korte interfererende nukleinsyrer (sina) |
EP2771463A4 (en) | 2011-10-25 | 2015-09-09 | Isis Pharmaceuticals Inc | ANTISENSE MODULATION OF GCCR EXPRESSION |
JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
CA3057154A1 (en) * | 2017-03-24 | 2018-09-27 | Gen-Probe Incorporated | Compositions and methods for detecting or quantifying parainfluenza virus |
LU100182B1 (en) * | 2017-04-06 | 2018-10-15 | Univ Hamburg Eppendorf Uke | Therapeutic use of microRNA 19A/19B |
US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
WO2020036862A1 (en) | 2018-08-13 | 2020-02-20 | Alnylam Pharmaceuticals, Inc. | HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5665550A (en) | 1990-10-19 | 1997-09-09 | Board Of Trustees Of The University Of Illinois-Urbana | Genes and genetic elements associated with sensitivity to chemotherapeutic drugs |
WO1994008003A1 (en) | 1991-06-14 | 1994-04-14 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE |
US5594076A (en) | 1991-09-24 | 1997-01-14 | The Pennsylvania Research Foundation | Hydrodegradable polyesters |
US6265157B1 (en) * | 1991-12-03 | 2001-07-24 | Allegheny University Of The Health Sciences | Compositions and methods for detecting altered COL1A1 gene sequences |
US20030073159A1 (en) | 1992-05-11 | 2003-04-17 | Human Genome Sciences, Inc. | Human inhibitor of apoptosis gene 1 |
EP0625159B1 (en) | 1992-09-14 | 2003-03-26 | The General Hospital Corporation | Ikaros: a regulatory gene involved in t-cell differentiation |
US6087173A (en) | 1999-09-09 | 2000-07-11 | Isis Pharmaceuticals Inc. | Antisense modulation of X-linked inhibitor of apoptosis expression |
US5958771A (en) | 1998-12-03 | 1999-09-28 | Isis Pharmaceuticals, Inc. | Antisense modulation of cellular inhibitor of Apoptosis-2 expression |
US5958772A (en) | 1998-12-03 | 1999-09-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of cellular inhibitor of apoptosis-1 expression |
WO1994023760A1 (en) | 1993-04-14 | 1994-10-27 | The United States Of America As Represented By The Secretary Of The Navy | Transgenic animal model for autoimmune diseases |
US5691179A (en) | 1993-08-26 | 1997-11-25 | Washington University | Cell death regulators |
US5624803A (en) * | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
US5510239A (en) | 1993-10-18 | 1996-04-23 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of multidrug resistance-associated protein |
WO1995019431A1 (en) | 1994-01-18 | 1995-07-20 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
EP0759090A4 (en) | 1994-04-13 | 2000-05-24 | Jolla Cancer Res Found | INTERACTION BETWEEN PROTEINS INFLUENCING THE CELL DEATH PROCESS |
SI9520059A (en) | 1994-05-10 | 1997-08-31 | Immulogic Pharma Corp | Compositions and treatment for multiple sclerosis. |
JP3944654B2 (ja) | 1994-10-18 | 2007-07-11 | ザ ユニバーシティー オブ オタワ | 神経細胞アポトーシスの抑制タンパクとその遺伝子配列、並びに脊髄性筋萎縮症の原因となる当該遺伝子の突然変異 |
SI9520118A (sl) | 1994-10-25 | 1998-08-31 | Immulogic Pharmaceutical Corporation | Sestavki in zdravljenje multiple skleroze |
AU4695296A (en) | 1995-01-06 | 1996-07-24 | Immulogic Pharmaceutical Corporation | Compositions and methods for treating rheumatoid arthritis |
CA2220670A1 (en) | 1995-05-11 | 1996-11-14 | Peter L. Hudson | Human inhibitor of apoptosis gene 1 |
US5770690A (en) | 1995-06-27 | 1998-06-23 | Neurex Corporation | Bax omega protein and methods |
US5877021A (en) * | 1995-07-07 | 1999-03-02 | Ribozyme Pharmaceuticals, Inc. | B7-1 targeted ribozymes |
US6156535A (en) | 1995-08-04 | 2000-12-05 | University Of Ottawa | Mammalian IAP gene family, primers, probes, and detection methods |
US5919912A (en) | 1995-08-04 | 1999-07-06 | University Of Ottawa | Mammalian IAP antibodies and diagnostic kits |
US6187557B1 (en) | 1995-08-08 | 2001-02-13 | Tularik Inc. | c-IAP1 and c-IAP2: inhibitors of apoptosis |
AU6692996A (en) | 1995-08-08 | 1997-03-05 | Tularik Inc. | Inhibitors of apoptosis |
US5834216A (en) | 1995-09-06 | 1998-11-10 | Arch Development Corporation | Screening methods for the identification of inducers and inhibitors of programmed cell death (apoptosis) |
AUPN727595A0 (en) | 1995-12-22 | 1996-01-18 | Walter And Eliza Hall Institute Of Medical Research, The | Therapeutic compositions |
US5605022A (en) | 1995-12-26 | 1997-02-25 | Nci Building Systems, Inc. | Vented closure |
GB9601108D0 (en) | 1996-01-19 | 1996-03-20 | Univ Ottawa | Neuronal apoptosis inhibitor protein (NAIP) |
US6133437A (en) | 1997-02-13 | 2000-10-17 | Apoptogen, Inc. | Modulation of IAPs for the treatment of proliferative diseases |
AU5065098A (en) | 1996-11-15 | 1998-06-10 | University Of Ottawa | Modulators of ovarial apoptosis related to iap |
US5994076A (en) | 1997-05-21 | 1999-11-30 | Clontech Laboratories, Inc. | Methods of assaying differential expression |
US6228603B1 (en) | 1997-05-22 | 2001-05-08 | The Burnham Institute | Screening assays for agents that alter inhibitor of apoptosis (IAP) protein regulation of caspase activity |
CA2225187A1 (en) | 1997-07-14 | 1999-01-14 | Universite D'ottawa/ University Of Ottawa | Xaf genes and polypeptides: methods and reagents for modulating apoptosis |
US6133246A (en) | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
AU1080899A (en) | 1997-10-14 | 1999-05-03 | Nadine A. Tatton | Methods for increasing schwann cell survival |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
JP2002512791A (ja) * | 1998-04-27 | 2002-05-08 | リボザイム・ファーマシューティカルズ・インコーポレーテッド | C型肝炎ウイルス感染に関連する疾患または状態の酵素的核酸治療 |
US6171821B1 (en) | 1998-07-24 | 2001-01-09 | Apoptogen, Inc. | XIAP IRES and uses thereof |
US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
AU1105800A (en) | 1998-10-09 | 2000-05-01 | L. Sai Latha Shankar | Methods for treating multiple sclerosis |
KR20000065690A (ko) | 1999-04-08 | 2000-11-15 | 박종구 | 반응 특이성 및 안정성을 개선시킨 안티센스 올리고 뉴클레오타이드, 안티센스 dna 및 그 제조방법 |
US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
US6395771B1 (en) | 2000-05-31 | 2002-05-28 | Dabur Research Foundation | Paclitaxel derivatives for the treatment of cancer |
US6673917B1 (en) * | 2000-09-28 | 2004-01-06 | University Of Ottawa | Antisense IAP nucleic acids and uses thereof |
US20020119168A1 (en) | 2001-02-20 | 2002-08-29 | Rudnic Edward M. | Therapeutic agent delivery |
KR100397275B1 (ko) | 2001-03-08 | 2003-09-17 | 주식회사 웰진 | 단방향성 안티센스 cDNA 라이브러리 구축을 통한 신규대규모 유전자 검색 및 기능 분석 시스템 |
AU2003228301A1 (en) | 2002-03-06 | 2003-09-22 | Rigel Pharmaceuticals, Inc. | Novel method for delivery and intracellular synthesis of sirna molecules |
NZ546807A (en) | 2002-03-27 | 2007-03-30 | Aegera Therapeutics Inc | Antisense IAP nucleobase oligomers and uses thereof |
EP1469070A1 (en) | 2003-04-15 | 2004-10-20 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Livin-specific siRNAs for the treatment of therapy-resistant tumors |
CA2539752A1 (en) | 2003-09-29 | 2005-04-07 | Topigen Pharmaceutique Inc. | Oligonucleotide compositions and methods for treating disease including inflammatory conditions |
US8012944B2 (en) | 2003-10-30 | 2011-09-06 | Pharmascience Inc. | Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent |
-
2003
- 2003-03-27 NZ NZ546807A patent/NZ546807A/en not_active IP Right Cessation
- 2003-03-27 DK DK03715244T patent/DK1490490T3/da active
- 2003-03-27 NZ NZ546806A patent/NZ546806A/en not_active IP Right Cessation
- 2003-03-27 ES ES03715244T patent/ES2325660T3/es not_active Expired - Lifetime
- 2003-03-27 AU AU2003219432A patent/AU2003219432B2/en not_active Ceased
- 2003-03-27 PT PT03715244T patent/PT1490490E/pt unknown
- 2003-03-27 EP EP03715244A patent/EP1490490B1/en not_active Expired - Lifetime
- 2003-03-27 AT AT03715244T patent/ATE431410T1/de active
- 2003-03-27 CN CN038124246A patent/CN1656222B/zh not_active Expired - Fee Related
- 2003-03-27 JP JP2003578391A patent/JP4486365B2/ja not_active Expired - Fee Related
- 2003-03-27 CA CA2480308A patent/CA2480308C/en not_active Expired - Fee Related
- 2003-03-27 IL IL16422803A patent/IL164228A0/xx unknown
- 2003-03-27 DE DE60327618T patent/DE60327618D1/de not_active Expired - Lifetime
- 2003-03-27 BR BR0308923-1A patent/BR0308923A/pt not_active IP Right Cessation
- 2003-03-27 MX MXPA04009361A patent/MXPA04009361A/es unknown
- 2003-03-27 US US10/400,382 patent/US7091333B2/en not_active Expired - Fee Related
- 2003-03-27 NZ NZ535461A patent/NZ535461A/en not_active IP Right Cessation
- 2003-03-27 WO PCT/IB2003/001670 patent/WO2003080638A2/en active Application Filing
-
2004
- 2004-09-22 ZA ZA200407649A patent/ZA200407649B/en unknown
- 2004-09-22 IL IL164228A patent/IL164228A/en not_active IP Right Cessation
-
2006
- 2006-05-30 US US11/442,380 patent/US20070032445A1/en not_active Abandoned
- 2006-06-08 US US11/448,862 patent/US7638620B2/en not_active Expired - Fee Related
- 2006-06-30 US US11/477,452 patent/US7638497B2/en not_active Expired - Fee Related
- 2006-10-26 US US11/586,554 patent/US20070135371A1/en not_active Abandoned
-
2009
- 2009-09-17 JP JP2009215798A patent/JP2010042009A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1490490T3 (da) | Antisense IAP--nukleobase-oligomerer og anvendelser deraf | |
NL301145I2 (nl) | Tirbanibulin | |
NO20091661L (no) | Anvendelse av pegylert IL-10 for a behandle kreft | |
PL380828A1 (pl) | Fosfoniany, amidomonofosfoniany, amidobisfosfoniany do leczenia chorób wirusowych | |
MX2008001652A (es) | Copolimeros de poliamonio-polisiloxano. | |
DK1866324T3 (da) | Phosphoramidatderivater af nukleosidforbindelser til anvendelse i behandlingen af cancer | |
TW200637522A (en) | Skin treatment articles and methods | |
AU2003272285A8 (en) | Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands | |
TW200518769A (en) | Use of calcitonin in osteoarthritis | |
ATE549024T1 (de) | Chinazolin-kaliumkanalhemmer | |
NO20053903D0 (no) | Nukleotidlipidesterderivater. | |
ITMI20031819A1 (it) | Dispositivo per la lavorazione di pezzi sostanzialmente piatti. | |
EP1667976A4 (en) | Isoquinolinone POTASSIUM CHANNEL INHIBITORS | |
WO2003105755A3 (en) | ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION | |
PL1843771T3 (pl) | Zastosowanie pirymidyloaminobenzamidów do leczenia chorób odpowiadających na modulację aktywności kinazy Tie-2 | |
NO20060420L (no) | 2-aminobenzoylderivater | |
DE602004019541D1 (de) | Cycloalkyläbü kondensierte indole | |
DK1223930T3 (da) | Behandling af dyskinesi | |
NO20072048L (no) | Anvendelse av IL-17F for behandling og/eller forebygging av neurologiske sykdommer. | |
MY166063A (en) | Intravenous antiviral treatments | |
ATE443138T1 (de) | Hemmung der expression von spag9 mit sirnas | |
ITPI20020050A1 (it) | Bottale per le lavorazioni delle pelli. | |
ES1052748Y (es) | Estacion depuradora de aguas residuales, mejorada. | |
UA32234A (uk) | Спосіб діагностики некласифікованого варіанта мієлодиспластичного синдрому як передстадії лейкемії у осіб, що зазнали дії іонізуючого опромінення | |
ITPI20020007A1 (it) | Apparato per la deumificazione di ambienti, in particolare per il trattamento delle pelli. |